OR WAIT 15 SECS
Fios Genomics, a spin-out bioinformatics company from Edinburgh University, has entered into a strategic partnership with Charles River Laboratories.
Fios Genomics, a spin-out bioinformatics company from Edinburgh University, has entered into a strategic partnership with Charles River Laboratories, it was announced in a Jan. 23, 2020 press release.
Under the terms of the partnership, Charles River clients will have access to Fios’ bioinformatics expertise to aid in both the sourcing and analysis of big data associated with drug development. Through the partnership, clients of Charles River are expected to benefit from being able to make more data-driven decisions about drug development programs and ultimately improve speed to market for the most suitable candidates.
“This partnership takes Fios to the next level, opening up opportunities for the business right around the world,” said Dr. Sarah Lynagh, CEO at Fios Genomics, in the press release. “Our approach to bioinformatics at Fios Genomics is to look beyond algorithms and statistics and understand that biological relevance and statistical significance are not necessarily the same thing. Bioinformatics is about biology, outcome and pathways, and by partnering with Charles River, we can help more researchers make data-driven decisions about their programs that are grounded in biological insights.
“The explosion in omics data has been a boon for the drug discovery industry, but analysis and interpretation of these datasets are challenging,” added Birgit Girshick, corporate executive vice-president, Discovery & Safety Assessment, Biologics Testing Solutions and Avian Vaccine Services at Charles River, in the press release. “Through our partnership with Fios Genomics, Charles River clients will have greater access to the special combination of skills in bioinformatics, statistics, and biology required to obtain meaningful information from their data.”
Source: Fios Genomics